| 초록 |
Unlike traditional approaches in oncology, cancer immunotherapy harnesses a patient’s coordinated and adaptive immune system in order to combat the disease. The benefits of cancer immunotherapy include the potential 1) to treat all types of cancer, regardless of the underlying mutations or cell of origin; 2) to prevent metastasis and relapse by generating memory antitumor immunity; and 3) to decrease side effects relative to conventional cytotoxic treatment. Still, the therapeutic index of cancer immunotherapy must be improved, since the proportion of patients responding to this approach remains unsatisfactory and the therapy often causes systemic toxicity following parental administration. To address these issues, we used various biomaterials-based drug delivery approaches to deliver immunomodulatory compounds in a spatiotemporally controlled manner in order to improve their efficacy and safety relative to conventional systemic administration. |
